Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $41.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: SYFOVRE; Analyst target reached - limited upside remaining.
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company with two approved complement-targeting drugs: SYFOVRE (intravitreal pegcetacoplan for GA, $586.9M U.S. net revenue in 2025) and EMPAVELI (subcutaneous pegcetacoplan for PNH/C3G/IC-MPGN, $102.4M). Sobi holds... Read more
Hold if already holding. Not a fresh buy at $41.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: SYFOVRE; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Apellis Pharmaceuticals, Inc.
Latest news
- Cantor Fitzgerald Suspends Neutral Rating on Apellis Pharmaceuticals — benzinga May 15, 2026 negative
- Why Is Biogen Stock Falling Thursday? — benzinga May 14, 2026 neutral
- Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy — benzinga May 8, 2026 neutral
- Apellis Pharmaceuticals Q1 EPS $0.15 Beats $(0.36) Estimate, Sales $268.295M Beat $205.185M Estimate — benzinga May 7, 2026 positive
- Remitly Global Set To Join S&P SmallCap 600 Will Replace Apellis Pharmaceuticals — benzinga May 7, 2026 neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductSYFOVRE10-K Item 1A: 'Our prospects depend substantially upon the commercial success of SYFOVRE.'
- MEDIUMcounterpartySobi10-K Item 1A: 'our ability to maintain a productive collaborative relationship with Sobi with respect to systemic pegcetacoplan, including our ability to achieve milestone payments under our agreement with Sobi'
Material Events(8-K, last 90d)
- 2026-03-31Item 1.01HIGHApellis entered into Agreement and Plan of Merger with Biogen Inc. on March 30, 2026. Biogen to acquire all outstanding shares at $41.00/share plus one CVR worth up to $4.00 in contingent milestone cash. Change of control transaction.SEC filing →
- 2026-05-04Item 5.02LOWCompensation committee approved amendment to Executive Separation Benefits Plan effective upon Biogen merger closing, accelerating vesting for Converted Options and RSU Awards on qualifying terminations.SEC filing →
- 2026-03-02Item 5.02LOWBoard elected Mikael Dolsten, M.D., Ph.D. as a Class I director effective March 1, 2026. Determined independent per Nasdaq rules; granted standard new director equity awards.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $41.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: SYFOVRE; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $40.32 (-1.8%), stop $40.91 (−0.4%), A.R:R -0.9:1. Score 5.8/10, moderate confidence.
Take-profit target: $40.32 (-1.7% upside). Target $40.32 (-1.8%), stop $40.91 (−0.4%), A.R:R -0.9:1. Stop-loss: $40.91.
Concentration risk — Product: SYFOVRE; Analyst target reached - limited upside remaining; Near 52-week high (0.3% away).
Apellis Pharmaceuticals, Inc. trades at a P/E of 38.3 (forward -103.1). TrendMatrix value score: 3.2/10. Verdict: Hold.
27 analysts cover APLS with a consensus score of 3.4/5. Average price target: $41.
What does Apellis Pharmaceuticals, Inc. do?Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company with two approved complement-targeting drugs:...
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company with two approved complement-targeting drugs: SYFOVRE (intravitreal pegcetacoplan for GA, $586.9M U.S. net revenue in 2025) and EMPAVELI (subcutaneous pegcetacoplan for PNH/C3G/IC-MPGN, $102.4M). Sobi holds exclusive ex-U.S. rights for systemic pegcetacoplan; Apellis agreed to be acquired by Biogen for $41/share plus CVR in March 2026.